Genhouse Bio Co. Ltd. closed a series A financing round to raise more than ¥200 million (US$31 million) to support phase I studies of KRAS inhibitor GH-35 and SHP2 inhibitor GH-21 in China. The startup expects to enroll patients in trials testing the two compounds in the second half of this year, CEO Wang Kuifeng told BioWorld in an exclusive interview.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Ambrx, Cygenica, Heartseed, Hifibio, Novocodex, Regencell Bioscience.
Umoja Biopharma Inc. has raised $210 million in a series B financing that will help it advance a pipeline of in vivo engineered CAR T-cell immunotherapies to the clinic, as well as build its internal manufacturing capabilities, it said. The Seattle-based company is focused on the treatment of solid tumors and hematologic malignancies. Softbank Vision Fund 2 and Cormorant Asset Management led the financing, the third largest series B round this year, according to BioWorld data. It follows a $53 million series A round the company announced in November 2020.
LONDON – The pioneers of gene therapy in Europe now aim to take the field to the next level, moving into the development of virally delivered antibodies in the treatment of central nervous system and muscular diseases, with Alzheimer’s disease one of the first targets.
LONDON – Alentis Therapeutics SA is now equipped to deliver initial proof of concept for its universal approach to treating fibrosis, after raising $67 million in an oversubscribed series B.
The hefty $107.5 million series B financing disclosed June 10 by Synthekine Inc. underscored Wall Street’s interest in engineered cytokines, where an army of companies is developing prospects at varying stages – including Bright Peak Therapeutics Inc., which pulled down a series B in almost exactly the same amount as Synthekine, and on the same day.
Biopharmas raising money in public or private financings, including: Ambrx, Cel-Sci, Century, Cyteir, Flagship, Hifibio, Inceptor, Isofol, Regencell, Synaptogenix, Verve.
RSS
